The Patent Finder

ANTI-CD3 Antibody Formulations

Tiziana Life Sciences PLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,688,186ANTI-CD3 Antibody Formulations
In force
 · High confidence
UsedRemaining
Tiziana Life Sciences PLCIn forceHigh confidence
Application 16/876,839ANTI-CD3 Antibody Formulations
Abandoned
Abandoned Mar 18, 2025
Tiziana Life Sciences PLCAbandonedAbandoned Mar 18, 2025
Application 19/048,132ANTI-CD3 Antibody Formulations
Abandoned
Abandoned May 26, 2026
Tiziana Life Sciences PLCAbandonedAbandoned May 26, 2026
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Tiziana Life Sciences PLC.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited